Imaging of Atherosclerosis With 68Ga-MSA

Korea University60 enrolled

Overview

Despite of intensive efforts, no specific ath¬erosclerosis-targeting agent labeled with positron emitter is not yet available. Fortunately, some scientists made the major advance in the field of clinical atherosclerosis molecular imaging by the metabolic PET reporter agent 18F(fluorine-18)-FDG(Fludeoxyglucose) applied to noninvasively image plaque macrophages in carotid arteries. However, coronary and cerebral arterial segments remain uninterpretable due to metabolic property of 18F-FDG. Applying the character of the terminal mannose residues of MSA binding with the mannose receptors of macrophages in atherosclerosis, we investigate whether 68Ga-MSA can be a novel agent for non-invasive molecular imaging of atherosclerotic lesion in PET.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Atherosclerosis Noninvasive Imaging of Atherosclerosis

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * acute coronary syndrome(acute myocardial infarction, unstable angina) * chronic stable angina * control without coronary artery disease Exclusion Criteria: * pregnancy, allergy to albumin, chronic inflammatory disease

Locations (1)

Outcomes

Primary Outcomes

comparison of SUV(standard uptake unit) at atherosclerotic plaque of aorta and carotid arteries among 3 groups

Time frame: 1 day at the time of PET(positron emission tomogram) imaging

Secondary Outcomes

side effect of PET imaging with 68Ga-MSA

any side effects including changes of biochemical values and vital signs

Time frame: with 7 days after PET imaging